Effects of the serotonin(2A/2C) receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex

Toshihide Kuroki, Takeshi Kawahara, Yuji Yonezawa, Nobutada Tashiro

研究成果: ジャーナルへの寄稿記事

14 引用 (Scopus)

抄録

1. Systemic administration of PCP (7.5 mg/kg, i.p.) produced a greater increase in extracellular DA levels in the mPFC than in the STR and NAC, as determined by in vivo microdialysis of awake, freely moving rats. Preferential activation by PCP of prefrontal DA neurons may be, at least in part, the basis for the pathophysiology of PCP-induced psychosis as well as schizophrenia. 2. Recent studies suggest a possible involvement of 5-HT(2A) receptors in the pathophysiology and treatment of schizophrenia. This study was designed to examine whether and how 5-HT(2A) receptors modulate PCP-induced DA release in the mPFC. 3. The 5-HT(2A/2C) receptor agonist (±)-DOI (2.5 mg/kg, but not 0.75 mg/kg, i.p.), administered 60 min prior to PCP, significantly attenuated the PCP-induced increase in extracellular DA levels. Pretreatment of the 5-HT(2A/2C) receptor antagonist ritanserin (1.0 and 5.0 mg/kg, i.p.), administered 60 min prior to PCP, did not influence the PCP-induced increase. When administered alone, neither DOI (2.5 mg/kg) nor ritanserin (1.0 mg/kg) affected basal extracellular DA levels in the mPFC. 4. The NMDA receptor antagonist MK-801 (1.0 mg/kg, i.p.) also increased extracellular DA levels in the mPFC, but this effect was unaffected by pretreatment with DOI (2.5 mg/kg). 5. These results suggest that the stimulation of 5-HT(2A/2C) receptors may inhibit DA release in the mPFC when it is facilitated by PCP. Other than the NMDA receptor-mediated mechanism may also be involved in the neurochemical interaction between 5-HT(2A) receptors and PCP in the mPFC.

元の言語英語
ページ(範囲)1259-1275
ページ数17
ジャーナルProgress in Neuro-Psychopharmacology and Biological Psychiatry
23
発行部数7
DOI
出版物ステータス出版済み - 10 1 1999
外部発表Yes

Fingerprint

Receptor, Serotonin, 5-HT2C
Receptor, Serotonin, 5-HT2A
Phencyclidine
Prefrontal Cortex
Dopamine
Ritanserin
N-Methyl-D-Aspartate Receptors
Schizophrenia
Dizocilpine Maleate
Microdialysis
Psychotic Disorders
Neurons

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Biological Psychiatry

これを引用

Effects of the serotonin(2A/2C) receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex. / Kuroki, Toshihide; Kawahara, Takeshi; Yonezawa, Yuji; Tashiro, Nobutada.

:: Progress in Neuro-Psychopharmacology and Biological Psychiatry, 巻 23, 番号 7, 01.10.1999, p. 1259-1275.

研究成果: ジャーナルへの寄稿記事

@article{b9ecae9fc662467ca15ad9a37606a6cd,
title = "Effects of the serotonin(2A/2C) receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex",
abstract = "1. Systemic administration of PCP (7.5 mg/kg, i.p.) produced a greater increase in extracellular DA levels in the mPFC than in the STR and NAC, as determined by in vivo microdialysis of awake, freely moving rats. Preferential activation by PCP of prefrontal DA neurons may be, at least in part, the basis for the pathophysiology of PCP-induced psychosis as well as schizophrenia. 2. Recent studies suggest a possible involvement of 5-HT(2A) receptors in the pathophysiology and treatment of schizophrenia. This study was designed to examine whether and how 5-HT(2A) receptors modulate PCP-induced DA release in the mPFC. 3. The 5-HT(2A/2C) receptor agonist (±)-DOI (2.5 mg/kg, but not 0.75 mg/kg, i.p.), administered 60 min prior to PCP, significantly attenuated the PCP-induced increase in extracellular DA levels. Pretreatment of the 5-HT(2A/2C) receptor antagonist ritanserin (1.0 and 5.0 mg/kg, i.p.), administered 60 min prior to PCP, did not influence the PCP-induced increase. When administered alone, neither DOI (2.5 mg/kg) nor ritanserin (1.0 mg/kg) affected basal extracellular DA levels in the mPFC. 4. The NMDA receptor antagonist MK-801 (1.0 mg/kg, i.p.) also increased extracellular DA levels in the mPFC, but this effect was unaffected by pretreatment with DOI (2.5 mg/kg). 5. These results suggest that the stimulation of 5-HT(2A/2C) receptors may inhibit DA release in the mPFC when it is facilitated by PCP. Other than the NMDA receptor-mediated mechanism may also be involved in the neurochemical interaction between 5-HT(2A) receptors and PCP in the mPFC.",
author = "Toshihide Kuroki and Takeshi Kawahara and Yuji Yonezawa and Nobutada Tashiro",
year = "1999",
month = "10",
day = "1",
doi = "10.1016/S0278-5846(99)00065-2",
language = "English",
volume = "23",
pages = "1259--1275",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Effects of the serotonin(2A/2C) receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex

AU - Kuroki, Toshihide

AU - Kawahara, Takeshi

AU - Yonezawa, Yuji

AU - Tashiro, Nobutada

PY - 1999/10/1

Y1 - 1999/10/1

N2 - 1. Systemic administration of PCP (7.5 mg/kg, i.p.) produced a greater increase in extracellular DA levels in the mPFC than in the STR and NAC, as determined by in vivo microdialysis of awake, freely moving rats. Preferential activation by PCP of prefrontal DA neurons may be, at least in part, the basis for the pathophysiology of PCP-induced psychosis as well as schizophrenia. 2. Recent studies suggest a possible involvement of 5-HT(2A) receptors in the pathophysiology and treatment of schizophrenia. This study was designed to examine whether and how 5-HT(2A) receptors modulate PCP-induced DA release in the mPFC. 3. The 5-HT(2A/2C) receptor agonist (±)-DOI (2.5 mg/kg, but not 0.75 mg/kg, i.p.), administered 60 min prior to PCP, significantly attenuated the PCP-induced increase in extracellular DA levels. Pretreatment of the 5-HT(2A/2C) receptor antagonist ritanserin (1.0 and 5.0 mg/kg, i.p.), administered 60 min prior to PCP, did not influence the PCP-induced increase. When administered alone, neither DOI (2.5 mg/kg) nor ritanserin (1.0 mg/kg) affected basal extracellular DA levels in the mPFC. 4. The NMDA receptor antagonist MK-801 (1.0 mg/kg, i.p.) also increased extracellular DA levels in the mPFC, but this effect was unaffected by pretreatment with DOI (2.5 mg/kg). 5. These results suggest that the stimulation of 5-HT(2A/2C) receptors may inhibit DA release in the mPFC when it is facilitated by PCP. Other than the NMDA receptor-mediated mechanism may also be involved in the neurochemical interaction between 5-HT(2A) receptors and PCP in the mPFC.

AB - 1. Systemic administration of PCP (7.5 mg/kg, i.p.) produced a greater increase in extracellular DA levels in the mPFC than in the STR and NAC, as determined by in vivo microdialysis of awake, freely moving rats. Preferential activation by PCP of prefrontal DA neurons may be, at least in part, the basis for the pathophysiology of PCP-induced psychosis as well as schizophrenia. 2. Recent studies suggest a possible involvement of 5-HT(2A) receptors in the pathophysiology and treatment of schizophrenia. This study was designed to examine whether and how 5-HT(2A) receptors modulate PCP-induced DA release in the mPFC. 3. The 5-HT(2A/2C) receptor agonist (±)-DOI (2.5 mg/kg, but not 0.75 mg/kg, i.p.), administered 60 min prior to PCP, significantly attenuated the PCP-induced increase in extracellular DA levels. Pretreatment of the 5-HT(2A/2C) receptor antagonist ritanserin (1.0 and 5.0 mg/kg, i.p.), administered 60 min prior to PCP, did not influence the PCP-induced increase. When administered alone, neither DOI (2.5 mg/kg) nor ritanserin (1.0 mg/kg) affected basal extracellular DA levels in the mPFC. 4. The NMDA receptor antagonist MK-801 (1.0 mg/kg, i.p.) also increased extracellular DA levels in the mPFC, but this effect was unaffected by pretreatment with DOI (2.5 mg/kg). 5. These results suggest that the stimulation of 5-HT(2A/2C) receptors may inhibit DA release in the mPFC when it is facilitated by PCP. Other than the NMDA receptor-mediated mechanism may also be involved in the neurochemical interaction between 5-HT(2A) receptors and PCP in the mPFC.

UR - http://www.scopus.com/inward/record.url?scp=0033201512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033201512&partnerID=8YFLogxK

U2 - 10.1016/S0278-5846(99)00065-2

DO - 10.1016/S0278-5846(99)00065-2

M3 - Article

C2 - 10581647

AN - SCOPUS:0033201512

VL - 23

SP - 1259

EP - 1275

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 7

ER -